Neil Dahiya

The Union Ministry of Commerce & Industry, through its Directorate General of Foreign Trade (DGFT), has released a notification unveiling changes to the ITC (HS) 2022, Schedule-I (Import Policy). These amendments bring the policy in line with the Finance Act […]

In India’s healthcare realm, technology is increasingly being utilized as a solution to tackle the diverse payment landscape, a consistent hurdle for patients, medical providers, and insurance companies. The issue stems from the existence of numerous payment systems, such as

The Bureau of Indian Standards (BIS), India’s foremost authority on standards, has pinpointed 214 essential medical devices for accelerated standards development, with completion expected by next year’s close. In harmony with the National Medical Device Policy, 2023, BIS is enhancing

Johnson & Johnson (J&J) India has initiated a nationwide program titled “India Identifies for Victory,” which underscores the vital significance of prompt detection and testing in enhancing lung cancer prognosis. The campaign’s initial phase involves a partnership with Amar Chitra

Centrum, the leading global multivitamin brand from Haleon (previously known as GlaxoSmithKline Consumer Healthcare), has introduced the Centrum Joint & Mobility Capsule. This cutting-edge product, featuring an exclusive blend of Undenatured Type II Collagen (UC-II) and vitamin K2, is crafted

Suraksha Diagnostic Limited is preparing to unveil its initial public offering (IPO) of equity shares, set to go live on Friday, November 29, 2024. Investors engaging as Anchor Bidders will have access one business day earlier, on Thursday, November 28,

As part of its Corporate Social Responsibility (CSR) initiatives, Bry-Air, the leading company of the Pahwa Group, organized its 14th Biannual Eye Clinic at Mathra Das Civil Eye Hospital in Moga, Punjab. This event was held in honor of the

Rajesh Narvekar has been named the newly appointed Commissioner of the Food and Drug Administration (FDA) by the Maharashtra government. He took over the responsibilities last week, occupying a position that remained unfilled since the retirement of former FDA Commissioner,

Glenmark Pharmaceuticals Inc., USA (Glenmark) has unveiled its new travoprost ophthalmic solution USP, 0.004% (ionic buffered solution), in the American market. This product is considered bioequivalent and therapeutically alike to the benchmark drug, Travatan Z ophthalmic solution USP, 0.004% by

Clinical-stage biotech firm Cassava Sciences, Inc., dedicated to pioneering innovative treatments for Alzheimer’s disease (AD) dementia, has disclosed that its phase 3 study, ReThink-ALZ, evaluating simufilam for mild-to-moderate AD, did not achieve its pre-set co-primary, secondary, and exploratory biomarker objectives.